RxDoctor Payments DataLook up a doctor →

Curtis Johnson, MD

Pain Medicine · Kansas City, MONPI 1619927225

Payments from drug & device makers

$461,807in general payments, 2019–2025

Across 350 payments — averaging $1319.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nevro Corp.$369K
  • Globus Medical$82K
  • Biotronik Inc.$7K
  • Boston Scientific$326
  • AbbVie$318
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$291
  • plus $2K from 34 others
$185in research payments, 2019–2025

Across 1 payment — averaging $185.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Saluda Medical Americas, Inc.$185

What the payments were for

  • Travel & lodging$1132%
  • Food & beverage$4,47198%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$461,807 in reported general payments places this provider in the 95th percentile of 124 pain medicine providers in Missouri.

See all pain medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$134,735
Medicare patients
468
Services billed
1,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen737$18,081
LyricaPregabalin18$10,728
NucyntaTapentadol Hcl12$7,895
ButransBuprenorphine14$7,563
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen298$5,992
Xtampza ErOxycodone Myristate14$5,355
MovantikNaloxegol Oxalate13$5,160
Hydrocodone-IbuprofenHydrocodone/Ibuprofen12$4,726
Lidocaine40$4,703
Fentanyl37$3,734
Gabapentin259$3,284
Buprenorphine22$2,605
Morphine Sulfate ErMorphine Sulfate111$2,546
Pregabalin129$2,299
Oxycodone Hcl122$2,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er$285$13,25026 claims
PfizerLyrica$137$10,72818 claims
Hikma Pharmaceuticals USABuprenorphine, Buprenorphine Hcl$19$2,67733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 124 pain medicine providers in Missouri.

Other pain medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →